- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04897035
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema (TIBER)
November 29, 2022 updated by: Koya Medical, Inc.
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Koya Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Koya Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Altos, California, United States, 94024
- PT works
-
Morgan Hill, California, United States, 95037
- Ginger-K Lymphedema & Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females ≥ 18 years of age
- Willing to sign the informed consent and deemed capable of following the study protocol
- Subjects must have a diagnosis of primary or secondary unilateral lower extremity edema
- At the time of initial evaluation, individuals must be at least 3 months post surgery, chemotherapy and/or radiation treatment for cancer if applicable
Exclusion Criteria:
- Individuals with a history or presence of an acute systemic disorder or condition that could place the patient at increased risk from sequential compression therapy
- Inability or unwillingness to participate in all aspects of study protocol and/or inability to provide informed consent
- Patients with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.)
- Patients must not have any diagnosed cognitive or physical impairment that would interfere with use of the device
- Diagnosis of lipedema
- Diagnosis of active or recurrent cancer (< 3 months since completion of chemotherapy, radiation therapy or primary surgery for the cancer)
- Diagnosis of Acute infection (in the last four weeks)
- Diagnosis of acute thrombophlebitis (in last 6 months)
- Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months
- Diagnosis of pulmonary edema
- Diagnosis of congestive heart failure (uncontrolled)
- Diagnosis of chronic kidney disease with acute renal failure
- Diagnosis of epilepsy
- Patients with poorly controlled asthma
- Any condition where increased venous and lymphatic return is undesirable
- Women who are pregnant, planning a pregnancy or nursing at study entry
- Participation in any clinical trial of an investigational substance or device during the past 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Subjects with Lower Extremity Lymphedema and phlebolymphedema
Lower Extremity Lymphedema and phlebolymphedema
|
Dayspring Active Wearable Compression System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LYMQOL (LYMphedema Quality of Life)
Time Frame: 3 months
|
The Lymphedema Quality of Life Questionnaire (LYMQOL), a validated disease-specific QoL tool, was also administered at baseline and at month 3. Overall QoL is scored on a single item by the patient on a scale of 1-10.
The outcome measure is assessed as a difference or change from baseline LYMQOL at day zero and month 3.
|
3 months
|
Limb Volume Maintenance or Improvement
Time Frame: 3 months
|
Limb volume measurement is performed by using a calibrated tape measure to measure circumference from the ankle and at 4cm increments to the waist region.
Measurements are taken for both lower extremities.
Volume is calculated based on cylindrical segment analysis.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/AEs
Time Frame: 3 months
|
As assessed by reported adverse events
|
3 months
|
Therapy adherence tracking
Time Frame: 3 months
|
Therapy adherence tracked via the mobile app that records usage per day.
Outcome measure will be evaluated based on recommended use of 45 minutes per day over the duration of 3 months.
|
3 months
|
Patient survey
Time Frame: 3 months
|
A visual analog scale (VAS) 1-5 and study survey were administered at the end of the study to measure patient satisfaction.
The six-item questionnaire was used to document the time of day the device was used, if daily activities were supported during use, function, and symptoms.
The VAS was administered to previous users of pneumatic compression devices to assess preference and likelihood to recommend to others with lymphedema.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 1, 2021
Primary Completion (ACTUAL)
June 30, 2022
Study Completion (ACTUAL)
July 1, 2022
Study Registration Dates
First Submitted
May 12, 2021
First Submitted That Met QC Criteria
May 20, 2021
First Posted (ACTUAL)
May 21, 2021
Study Record Updates
Last Update Posted (ACTUAL)
December 1, 2022
Last Update Submitted That Met QC Criteria
November 29, 2022
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KCT 006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphedema
-
Lymphatica Medtech SATerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmSwitzerland
-
Tactile MedicalVanderbilt University Medical CenterRecruitingLymphedema | Lymphedema, Secondary | Lymphedema; Surgical | Lymphedema of Face | Lymphedema Due to RadiationUnited States
-
ThuasneUniversity Hospital, Tours; Delta ConsultantsCompletedLymphedema, Secondary | Lymphedema of Leg | Lymphedema Congenital | Lymphedema PrimaryFrance
-
Maastricht University Medical CenterRadboud University Medical Center; Erasmus Medical CenterRecruitingLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmNetherlands
-
Odense University HospitalDanish Cancer SocietyActive, not recruitingPathologic Processes | Neoplasms | Skin Diseases | Lymphatic Diseases | Postoperative Complications | Breast Cancer | Breast Diseases | Lymphedema | Breast Neoplasm | Surgery | Secondary Lymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema Arm | Iatrogenic Lymphedema | A... and other conditionsDenmark
-
Swansea Bay University Health BoardSwansea University; Huntleigh Healthcare Ltd; Lymphoedema Wales Clinical NetworkCompleted
-
ResMedLymphatic Solutions, LLCCompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema PrimaryUnited States
-
University of OttawaMcGill University; Horizon Health Network; University of New Brunswick; New Brunswick...UnknownLymphedema of Upper Limb | Mastectomy Related Lymphedema | Lymphedema of Lower Extremity
-
Odense University HospitalZealand University Hospital; Vejle Hospital; Herlev and Gentofte HospitalRecruitingLymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema Arm | Lymphedema; SurgicalDenmark
-
University Hospital, MontpellierCompletedPrimary Lymphedema Secondary LymphedemaFrance
Clinical Trials on Dayspring Active Wearable Compression System
-
Koya Medical, Inc.RecruitingLymphedema | Lymphedema, Breast Cancer | Lymphedema ArmUnited States
-
Kowloon Hospital, Hong KongChinese University of Hong Kong; Kwong Wah HospitalCompletedStroke | Foot Drop (Acquired)Hong Kong
-
EtectRX, Inc.Quotient SciencesCompletedHealthy VolunteersUnited States
-
New York Institute of TechnologyTerminatedSedentary Behavior | Compression; Vein | Compression; Artery | DVT of LegsUnited States
-
Riphah International UniversityRecruiting
-
Tel-Aviv Sourasky Medical CenterOwlytics HealthcareRecruiting
-
Sensible Medical Innovations Ltd.Terminated
-
Lisa BrennerApollo NeuroscienceCompleted
-
Show Chwan Memorial HospitalCompletedDeep Venous ThrombosisTaiwan